DetermaRx™ is a 14-gene molecular treatment stratification test to identify patients with Stage IA, IB and IIA non-squamous NSCLC with a tumor size of less than 5cm and with no nodal involement (N0), who have undergone surgical resection and are now being considered for chemotherapy in the next stage of their care. It has outperformed NCCN criteria in identifying patients at high risk for mortality from stage IA, IB, and IIA non-squamous NSCLC. It was
formerly known as the Razor treatment stratification test.
Lung Adenocarcinoma, Lung Non-Squamous Non-Small Cell Cancer, Non Small Cell Lung Cancer